IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

IN RE COPAXONE 40 MG CONSOLIDATED) CASES)	C.A. No. 14-1171-GMS
	(CONSOLIDATED)

NOTICE OF APPEAL

Notice is hereby given that Plaintiffs Teva Pharmaceuticals USA, Inc., Teva
Pharmaceutical Industries, Ltd., Teva Neuroscience, Inc. and Yeda Research and Development
Co. Ltd. hereby appeal to the United States Court of Appeals for the Federal Circuit from the
Final Judgment entered in the above-captioned consolidated actions on January 31, 2017 (Docket
Entry No. 299), including all interlocutory decisions and orders subsidiary thereto and subsumed
therein and all adverse orders, decisions and opinions of the Court in this matter, including the
Order (Docket Entry No. 295) and Memorandum (Docket Entry No. 294) entered on January 30,
2017.

Included herewith is payment of the filing fee (\$5.00) and the docketing fee (\$500.00) as required by 28 U.S.C. § 1917, Federal Circuit Rule 52(a)(3)(A), Federal Rule of Appellate Procedure 3(e), and the United States District Court for the District of Delaware fee schedule (effective December 1, 2013).

Respectfully submitted,

OF COUNSEL:
David M. Hashmall
Elizabeth J. Holland
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405

Paul F. Ware
Daryl L. Wiesen
John T. Bennett
Nicholas K. Mitrokostas
GOODWIN PROCTER LLP
100 Northern Ave.
Boston, MA 02110
(617) 570-1000

(212) 813-8800

William G. James GOODWIN PROCTER LLP 901 New York Avenue, NW Washington, DC 20001 (202) 346-4000

Dated: February 2, 2017

/s/ Karen E. Keller

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
David M. Fry (No. 5486)
SHAW KELLER LLP
300 Delaware Avenue, Suite 1120
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
dfry@shawkeller.com

Richard D. Kirk (No. 922)
Stephen B. Brauerman (No. 4952)
BARYARD, P.A.
222 Delaware Avenue, Suite 900
Wilmington, DE 19801
(302) 655-5000
rkirk@bayardlaw.com
sbrauerman@bayardlaw.com

Attorneys for Plaintiffs Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., Teva Neuroscience, Inc. and Yeda Research & Development Co.